JP2023542296A5 - - Google Patents
Info
- Publication number
- JP2023542296A5 JP2023542296A5 JP2023516479A JP2023516479A JP2023542296A5 JP 2023542296 A5 JP2023542296 A5 JP 2023542296A5 JP 2023516479 A JP2023516479 A JP 2023516479A JP 2023516479 A JP2023516479 A JP 2023516479A JP 2023542296 A5 JP2023542296 A5 JP 2023542296A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- gene mutation
- gene
- fgfr3
- fgfr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078193P | 2020-09-14 | 2020-09-14 | |
| US63/078,193 | 2020-09-14 | ||
| PCT/EP2021/075145 WO2022053697A1 (en) | 2020-09-14 | 2021-09-13 | Fgfr inhibitor combination therapies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023542296A JP2023542296A (ja) | 2023-10-06 |
| JP2023542296A5 true JP2023542296A5 (https=) | 2024-09-26 |
Family
ID=77821784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023516479A Pending JP2023542296A (ja) | 2020-09-14 | 2021-09-13 | Ｆｇｆｒ阻害剤の併用療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230321087A1 (https=) |
| EP (1) | EP4210702A1 (https=) |
| JP (1) | JP2023542296A (https=) |
| KR (1) | KR20230069958A (https=) |
| CN (1) | CN116669763A (https=) |
| AU (1) | AU2021339962A1 (https=) |
| CA (1) | CA3191538A1 (https=) |
| MX (1) | MX2023002980A (https=) |
| TW (1) | TW202228695A (https=) |
| WO (1) | WO2022053697A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202308689A (zh) * | 2021-04-21 | 2023-03-01 | 美商健生生物科技公司 | 高濃度的雙特異性抗體調配物 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2156149T3 (es) | 1992-12-04 | 2001-06-16 | Medical Res Council | Proteinas de union multivalente y multiespecificas, su fabricacion y su uso. |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| EP0951541B1 (en) | 1995-07-31 | 2005-11-30 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| WO2005110076A2 (en) | 2004-05-10 | 2005-11-24 | Children's Medical Center Corporation | Braf expression in zebrafish and uses thereof |
| EP3042964A1 (en) | 2004-06-04 | 2016-07-13 | Genentech, Inc. | Egfr mutations |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| BRPI0611375A2 (pt) | 2005-05-23 | 2010-08-31 | Novartis Ag | formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona |
| US8163923B2 (en) | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
| AU2008343589A1 (en) | 2007-12-19 | 2009-07-09 | Centocor Ortho Biotech Inc. | Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| EP2714738B1 (en) | 2011-05-24 | 2018-10-10 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
| MX361088B (es) * | 2012-11-21 | 2018-11-26 | Janssen Biotech Inc | Anticuerpos del receptor del factor de crecimiento epidérmico aislado/del receptor del factor de crecimiento de hepatocitos (egfr/c-met) biespecíficos. |
| KR102470456B1 (ko) | 2014-09-26 | 2022-11-23 | 얀센 파마슈티카 엔.브이. | Fgfr 억제제를 사용한 치료에 반응할 암 환자를 확인하는 데 있어서 fgfr 돌연변이 유전자 패널의 사용 |
| HUE054848T2 (hu) | 2014-10-13 | 2021-09-28 | Yuhan Corp | Vegyületek és készítmények EGFR mutáns kináz aktivitás módosítására |
| EP3277689B1 (en) * | 2015-04-03 | 2019-09-04 | Incyte Corporation | Heterocyclic compounds as lsd1 inhibitors |
| MA43416A (fr) * | 2015-12-11 | 2018-10-17 | Regeneron Pharma | Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3 |
| CN110869392A (zh) * | 2017-05-16 | 2020-03-06 | 百时美施贵宝公司 | 用抗gitr激动性抗体治疗癌症 |
| CN111868260B (zh) * | 2017-08-07 | 2025-02-21 | 约翰斯霍普金斯大学 | 用于评估和治疗癌症的方法和材料 |
| EP3898626A1 (en) * | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
| MA55486A (fr) * | 2019-03-29 | 2022-02-09 | Janssen Pharmaceutica Nv | Inhibiteurs de la tyrosine kinase fgfr pour le traitement du carcinome urothélial |
| WO2020208592A1 (en) * | 2019-04-12 | 2020-10-15 | Dr. Reddy’S Laboratories Limited | Process for preparation of erdafitinib, its purification and amorphous solid dispersion |
| CN111420060B (zh) * | 2020-03-30 | 2022-04-08 | 南方医科大学南方医院 | 一种抗肿瘤的联合用药组合物及其应用 |
-
2021
- 2021-09-13 EP EP21773119.9A patent/EP4210702A1/en active Pending
- 2021-09-13 KR KR1020237012158A patent/KR20230069958A/ko not_active Withdrawn
- 2021-09-13 CA CA3191538A patent/CA3191538A1/en active Pending
- 2021-09-13 AU AU2021339962A patent/AU2021339962A1/en not_active Abandoned
- 2021-09-13 US US18/044,232 patent/US20230321087A1/en active Pending
- 2021-09-13 CN CN202180076145.8A patent/CN116669763A/zh active Pending
- 2021-09-13 MX MX2023002980A patent/MX2023002980A/es unknown
- 2021-09-13 JP JP2023516479A patent/JP2023542296A/ja active Pending
- 2021-09-13 WO PCT/EP2021/075145 patent/WO2022053697A1/en not_active Ceased
- 2021-09-14 TW TW110134269A patent/TW202228695A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tao et al. | Cancer associated fibroblasts: An essential role in the tumor microenvironment | |
| US9242000B2 (en) | Micro-RNAs and micro-RNA inhibitors to modulate blood vessel growth, patterning, tumor growth and malignant disease and method for making and using them | |
| Diaz-Rubio et al. | Capecitabine (Xeloda®) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors | |
| JP2018508469A5 (https=) | ||
| Ho et al. | Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor | |
| US20240108628A1 (en) | Combination therapy with mek inhibitor and cdk4/6 inhibitor to treat pancreatic cancer | |
| CN111032082B (zh) | Her2阳性癌症的治疗 | |
| JP7520366B2 (ja) | 腫瘍療法の副作用の予防または治療方法 | |
| Symonds et al. | Combined targeted therapies for first-line treatment of metastatic triple negative breast cancer—a phase II trial of weekly nab-paclitaxel and bevacizumab followed by maintenance targeted therapy with bevacizumab and erlotinib | |
| CN110996927A (zh) | 复发性胶质母细胞瘤(rgbm)的治疗方法 | |
| JP2020505425A5 (https=) | ||
| JP2022527482A5 (https=) | ||
| Ahn et al. | Clinical activity of TGF-β inhibitor vactosertib in combination with imatinib in desmoid tumors: a multicenter phase Ib/II study | |
| Gordon et al. | Phase I open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of dilpacimab in patients with advanced solid tumors | |
| Zhou et al. | The present roles and future perspectives of Interleukin-6 in biliary tract cancer | |
| JP2023542296A5 (https=) | ||
| JP2023513298A5 (https=) | ||
| CN107949401A (zh) | 联合施用酪氨酸激酶抑制剂来抑制表皮生长因子/表皮生长因子受体途径的方法及组合物 | |
| US20230097085A1 (en) | [6r]-mthf in 5-fu based chemotherapy of right-sided colorectal cancer | |
| TW201521742A (zh) | 具降低毒性之庫司替森（ｃｕｓｔｉｒｓｅｎ）療法 | |
| Leong et al. | Effects of toceranib compared with sorafenib on monocrotaline-induced pulmonary arterial hypertension and cardiopulmonary remodeling in rats | |
| WO2021073535A1 (zh) | 预防或治疗与vegfr和/或vegf被抑制相关疾病的方法 | |
| US20210379095A1 (en) | Methods and Combination Therapy to Treat Biliary Tract Cancer | |
| US20230102483A1 (en) | [6r]-mthf in 5-fu based chemotherapy of left-sided colorectal cancer | |
| US20220348662A1 (en) | Use of fgfr inhibitors in fgfr-genetically altered cancers to enhance patient response to immune checkpoint inhibitors in sequential treatment settings |